Codes ATC:
N07AA01
EMLc
Indication
Anticholinesterase reversible
Code ICD11:
XM9D92
INN
Neostigmine bromide
Type de médicament
Chemical agent
Type de liste
Liste de base
(EML)
(EMLc)
(EMLc)
Formulations
Oral > Solid:
15 mg (neostigmine bromide)
Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate) ; 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate) ; 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
Historique des statuts LME
Sexe
Tous
Âge
Aussi recommandé pour les enfants
Équivalence thérapeutique
La recommandation concerne ce médicament spécifique
Renseignements sur le brevet
Patents have expired in most jurisdictions
Lire la suite
sur les brevets.
Wikipédia
DrugBank
Résumé des preuves et recommandation du comité d'experts
The EMLc Subcommittee noted that neostigmine metilsulfate injection was the preferred agent for the reversal of non-depolarising muscle block and endorsed neostigmine injection for inclusion in the EMLc. While neostigmine bromide tablets are licensed for use in infants and children for the treatment of myasthenia gravis, the Subcommittee noted that pyridostigmine has fewer cholinergic adverse effects and is now regarded as the first-line drug treatment for myasthenia gravis. The Subcommittee endorsed neostigmine (injection and tablet forms) and pyridostigmine (injection and tablet forms) for inclusion in the EMLc, with the latter retained in the Complementary List.